Noticias de XTLB_US

Noticias del mercado

Últimas noticias sobre XTLB_US — 64 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: XTLB_US ✕ 64 resultados
15/05/2026 XTLB_US — TipRanks ES ← EN
XTL Biopharmaceuticals convoca una reunión el 22 de junio de 2026 para aprobar la adquisición de Psyga Bio y el aumento de capital

XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise

15/05/2026 XTLB_US — Investing.com ES ← EN
XTL Biopharmaceuticals programa junta extraordinaria de accionistas para el 22 de junio

XTL Biopharmaceuticals schedules extraordinary shareholder meeting for June 22

15/05/2026 XTLB_US — Stock Titan ES ← EN
La adquisición de Psyga y la colocación privada de 1,5 millones de dólares están sometidas al voto de los accionistas de XTLB

Psyga acquisition and US$1.5M private placement up for XTLB shareholder vote

12/05/2026 XTLB_US — TradingKey ES ← EN
Clave comercial

TradingKey

07/05/2026 XTLB_US — TipRanks ES ← EN
XTL Biopharmaceuticals gana un aplazamiento condicional de cotización en Nasdaq vinculado al acuerdo de Psyga Bio

XTL Biopharmaceuticals Wins Conditional Nasdaq Listing Reprieve Tied to Psyga Bio Deal

07/05/2026 XTLB_US — Investing.com Nigeria
Nasdaq grants XTL Biopharmaceuticals conditional extension for continued listing By Investing.com
07/05/2026 XTLB_US — Investing.com
Nasdaq grants XTL Biopharmaceuticals conditional extension for continued listing
07/05/2026 XTLB_US — Investing.com ES ← EN
Nasdaq otorga a XTL Biopharmaceuticals una extensión condicional para continuar cotizando

Nasdaq grants XTL Biopharmaceuticals conditional extension for continued listing

07/05/2026 XTLB_US — Stock Titan
Conditional Nasdaq lifeline for XTL Biopharmaceuticals (NASDAQ: XTLB) tied to Psyga deal
04/05/2026 XTLB_US — Mugglehead Investment Magazine
XTL Biopharma to enter psychedelics sector with Psyga Bio takeover
30/04/2026 XTLB_US — TipRanks
XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation
29/04/2026 XTLB_US — Newser ES ← EN
XTLB (XTL) destaca el progreso prometedor de la cartera biofarmacéutica junto con sus últimos resultados de ganancias trimestrales. - Rendimiento del FCF

XTLB (XTL) highlights promising biopharma pipeline progress alongside its latest quarterly earnings results. - FCF Yield

29/04/2026 XTLB_US — Newser ES ← EN
XTLB (XTL) destaca el progreso prometedor de la cartera biofarmacéutica junto con sus últimos resultados de ganancias trimestrales. - Alertas de riesgo de multitudes

XTLB (XTL) highlights promising biopharma pipeline progress alongside its latest quarterly earnings results. - Crowd Risk Alerts

29/04/2026 XTLB_US — Investing.com South Africa ES ← EN
XTL Biopharmaceuticals adquirirá Psyga Bio por una participación del 40% Por Investing.com

XTL Biopharmaceuticals to acquire Psyga Bio for 40% stake By Investing.com

29/04/2026 XTLB_US — The Manila Times
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
29/04/2026 XTLB_US — newser.com
XTLB (XTL) highlights promising biopharma pipeline progress alongside its latest quarterly earnings results. - Social Buzz Stocks
29/04/2026 XTLB_US — Yahoo Finance
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
29/04/2026 XTLB_US — newser.com
XTLB (XTL) highlights promising biopharma pipeline progress alongside its latest quarterly earnings results. - Expert Stock Picks
29/04/2026 XTLB_US — Stock Titan
Seven Phase 2a psychedelic trials ride with XTL’s planned Psyga buy
29/04/2026 XTLB_US — Quiver Quantitative
XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement

Página 1 de 4

keyboard_arrow_up